中轴型脊柱关节炎治疗与髋部及脊柱骨折风险的关联
该巢式病例对照研究利用2006至2021年Merative MarketScan数据库,纳入13,519例18至65岁中轴型脊柱关节炎患者,其中骨折病例1,229例、对照12,290例。与使用非甾体抗炎药者相比,接受肿瘤坏死因子抑制剂者骨折风险降低(OR 0.71,95%CI 0.59-0.85),完全校正模型结果相似(OR 0.75,95%CI 0.62-0.91)。
要点
- 接受肿瘤坏死因子抑制剂者较使用非甾体抗炎药者骨折风险降低(OR 0.71,95%CI 0.59-0.85)。
- 完全校正年龄、性别和诊断年份后结果相似(OR 0.75,95%CI 0.62-0.91)。
- 按性别分层后结果相似。
核心结论
- 基于美国大型保险理赔数据库,接受肿瘤坏死因子抑制剂对中轴型脊柱关节炎患者骨折风险具有保护作用的证据,提示肿瘤坏死因子抑制剂可能有助于减少与中轴型脊柱关节炎相关的合并症。
研究设计与样本
- 巢式病例对照研究,使用2006至2021年Merative MarketScan数据库数据。
- 纳入18至65岁、至少有1次住院或至少2次门诊中轴型脊柱关节炎ICD-9或ICD-10诊断代码(间隔至少7天)的成人。
- 主要结局为髋部和/或脊柱骨折,由ICD-9或ICD-10诊断或操作代码定义;每例骨折患者匹配最多10例无骨折对照。
- 采用非条件logistic回归并校正混杂因素评估用药暴露与髋部和脊柱骨折风险的关系。
- 主要分析纳入13,519例中轴型脊柱关节炎患者,包括1,229例骨折患者和12,290例对照。
主要发现
- 接受肿瘤坏死因子抑制剂者较使用非甾体抗炎药者骨折风险降低29%(OR 0.71,95%CI 0.59-0.85),校正年龄、性别和诊断年份。
- 完全校正模型中结果相似(OR 0.75,95%CI 0.62-0.91)。
- 按性别分层后结果相似。
关键数值与推荐
- 中轴型脊柱关节炎诊断需至少1次住院或至少2次门诊ICD-9或ICD-10诊断代码,且间隔至少7天。
- 主要结局髋部和/或脊柱骨折由ICD-9或ICD-10诊断或操作代码定义。
- 用药暴露按层级评估:肿瘤坏死因子抑制剂、传统合成改善病情抗风湿药、非甾体抗炎药(参照)或无。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: People with axial spondyloarthritis (axSpA) have increased fracture risk relative to the general population, possibly related to chronic inflammation. We assessed the impact of treatment with receiving tumor necrosis factor inhibitors (TNFis) and nonbiologic conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on hip and spine fractures in patients with axSpA, relative to receiving nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS: We conducted a nested case-control study using 2006 to 2021 data from the Merative MarketScan Database. We included adults 18 to 65 years old with at least one inpatient or at least two outpatient axSpA International Classification of Diseases, Ninth Revision (ICD-9), or International Classification of Diseases, Tenth Revision (ICD-10), diagnosis codes separated by at least seven days. The primary outcome was hip and/or spine fracture, defined by ICD-9 or ICD-10 diagnosis or procedure codes. For each patient with fracture (cases), we selected up to 10 controls without fracture. We evaluated medication exposure (TNFis, csDMARDs, NSAIDs [referent], or none) hierarchically using pharmacy claims and procedure codes. We assessed the relation of medication exposure with hip and spine fracture risk using unconditional logistic regression with confounder adjustment. RESULTS: Our main analysis included 13,519 individuals with axSpA, comprising 1,229 patients with fracture and 12,290 controls. Individuals receiving TNFis had 29% lower odds of fracture compared to those receiving NSAIDs (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.59-0.85), accounting for age, sex, and diagnosis year. Results were similar in the fully adjusted model (OR 0.75, 95% CI 0.62-0.91) and when stratified by sex. CONCLUSION: Using a large US insurance claims database, we found evidence for a protective effect of receiving TNFis on fracture risk in patients with axSpA underscoring a potential impact of TNFis in diminishing comorbidities linked with axSpA.
引用
- Driscoll D, George N, Peloquin C, et al. Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures. Arthritis Rheumatol. 2025. PMID: 39679763. doi:10.1002/art.43082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。